UHS HOSPITALS
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $1.1M
- Transactions
- 414
- Companies
- 40
- Average per transaction
- $2,731
Who reported the payments
| Ortho-clinical Diagnostics, Inc. | $284,260 |
| Qiagen, LLC | $226,374 |
| AbbVie | $106,290 |
| Quidel Corporation | $78,468 |
| Novartis | $60,811 |
| Barco, Inc. | $51,035 |
| Abbott | $35,401 |
| Indivior Inc. | $28,678 |
| Meridian Bioscience Inc. | $28,501 |
| Sterilmed, Inc. | $24,315 |
| Edwards Lifesciences | $21,500 |
| Olympus America Inc. | $18,000 |
| AstraZeneca | $15,500 |
| Zimmer Biomet | $14,435 |
| Pfizer | $13,500 |
| E.r. Squibb & Sons, L.L.C. | $10,500 |
| Janssen Research & Development, LLC | $10,500 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | $8,000 |
| Amgen | $7,505 |
| Merge Healthcare Incorporated | $7,098 |
| Boehringer Ingelheim | $7,000 |
| Ironwood Pharmaceuticals, Inc | $6,822 |
| Daiichi Sankyo Inc. | $6,000 |
| Stryker | $5,468 |
| Sanofi | $5,000 |
| Seagen Inc. | $5,000 |
| Biosense Webster, Inc. | $4,500 |
| Johnson & Johnson | $3,500 |
| Genentech USA, Inc. | $3,000 |
| Pharmacyclics LLC, An Abbvie Company | $3,000 |
| Lilly USA, LLC | $3,000 |
| Merck | $2,950 |
| Bridgebio Pharma, Inc. | $2,500 |
| Actelion Pharmaceuticals US, Inc. | $2,500 |
| Aesculap, Inc. | $2,261 |
| Smith+Nephew | $2,234 |
| Alnylam Pharmaceuticals Inc. | $2,000 |
| Morphosys, US Inc. | $2,000 |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,000 |
| Adaptive Biotechnologies Corporation | $2,000 |